SCHEMBL360511

SCHEMBL360511

CC(Br)OCc1ccccc1

nearest known ligand 0.48

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
TSHR P16473 2/20 0.48
IDO1 P14902 1/20 0.44
SLC1A3 P43003 2/20 0.43
SLC1A2 P43004 2/20 0.43
SLC1A1 P43005 2/20 0.43
MEN1 O00255 1/20 0.43
CYP1A2 P05177 1/20 0.43
CYP2D6 P10635 1/20 0.43
CYP2C9 P11712 1/20 0.43
CYP2C19 P33261 1/20 0.43
KMT2A Q03164 1/20 0.43
AGXT P21549 1/20 0.43
MAPT P10636 2/20 0.42
ALDH1A1 P00352 2/20 0.42
RCE1 Q9Y256 1/20 0.41
SLC6A2 P23975 3/20 0.41
TAAR1 Q96RJ0 3/20 0.41
SLC6A4 P31645 2/20 0.41
SLC6A3 Q01959 2/20 0.41
MAOA P21397 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4970198 0.83 RCE1 (0.46) TSHRIDO1SLC1A3SLC1A2SLC1A1
SCHEMBL7325232 0.83 TSHR (0.44) TSHRIDO1SLC1A3SLC1A2SLC1A1
SCHEMBL26692829 0.82 TSHR (0.50) TSHRIDO1KMT2AALDH1A1TDP1
SCHEMBL96685 0.82 TSHR (0.48) TSHRIDO1SLC1A3SLC1A2SLC1A1
SCHEMBL15003 0.81 TSHR (0.52) TSHRIDO1SLC1A3SLC1A2SLC1A1
SCHEMBL1571975 0.81 TSHR (0.52) TSHRIDO1SLC1A3SLC1A2SLC1A1
SCHEMBL28631602 0.81 TSHR (0.52) TSHRIDO1SLC1A3SLC1A2SLC1A1
SCHEMBL27700953 0.81 MAPT (0.54) TSHRIDO1SLC1A3SLC1A2SLC1A1
SCHEMBL1965633 0.79 RCE1 (0.44) TSHRIDO1SLC1A3SLC1A2SLC1A1
SCHEMBL8330569 0.79 RCE1 (0.44) TSHRIDO1SLC1A3SLC1A2SLC1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 124 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2012006783-A1 PROCESS FOR PRODUCTION OF HYDROXYTYROSOL USING ORGANOMETALLIC COMPOUNDS LONZA LTD (CH) 2012-01-19 WO claimed
EP-4736848-A1 PHARMACEUTICAL COMPOSITION CONTAINING CATIONIC LIPID AND USE THEREOF Shanghai Regenelead Therapies Co., Ltd. (CN) 2026-05-06 EP disclosed
US-20260092031-A1 METHOD FOR PREPARING 2-HYDROXYETHYL AMINOCAPROATE COMPOUND AND USE THEREOF SUZHOU SUNCADIA BIOPHARMACEUTICALS CO LTD (CN) 2026-04-02 US disclosed
CN-119731149-A Method for preparing 2-hydroxyethyl amino caproate compound and application thereof 苏州盛迪亚生物医药有限公司 2025-03-28 CN disclosed
US-20250064750-A1 LIPID AND COMPOSITION USED FOR DELIVERY JIANGSU HENGRUI PHARMACEUTICALS CO., LTD. (CN) 2025-02-27 US disclosed
US-20250034120-A1 PYRIDAZINONES AS PARP7 INHIBITORS RIBON THERAPEUTICS, INC. 2025-01-30 US disclosed
WO-2025002352-A1 PHARMACEUTICAL COMPOSITION CONTAINING CATIONIC LIPID AND USE THEREOF 上海瑞宏迪医药有限公司 2025-01-02 WO disclosed
EP-4458806-A1 LIPID AND COMPOSITION USED FOR DELIVERY Jiangsu Hengrui Pharmaceuticals Co., Ltd. (CN) 2024-11-06 EP disclosed
WO-2024061204-A1 METHOD FOR PREPARING 2-HYDROXYETHYL AMINOCAPROATE COMPOUND AND USE THEREOF 苏州盛迪亚生物医药有限公司 2024-03-28 WO disclosed
CN-117700374-A Preparation method of chiral high morpholine-3-formic acid 吉尔多肽生物制药(大连市)有限公司 2024-03-15 CN disclosed
US-5817693-A Endothelin receptor antagonists SMITHKLINE BEECHAM CORPORATION 1998-10-06 US disclosed
US-5789434-A ACID, ESTER OR AMIDE DERIVATIVES AS ANTIINFLAMMATORY AGENTS, ANTIARTHRITIC AGENTS AND REDUCTION OF CARTILAGE DETERIORATION BAYER CORPORATION (US) 1998-08-04 US disclosed
US-5719182-A TREATING HYPERTENSION, RENAL FAILURE, CEREBROVASCULAR DISEASE SMITHKLINE BEECHAM CORPORATION (US) 1998-02-17 US disclosed
US-5719183-A HYPOTENSIVE AGENTS; KIDNEY DISEASES; ANTIISCHEMIC AGENTS SMITHKLINE BEECHAM CORPORATION (US) 1998-02-17 US disclosed
US-5716985-A INDANE AND INDENE DERIVATIVES SMITHKLINE BEECHAM CORPORATION (US) 1998-02-10 US disclosed
US-5716984-A INDANE AND INDENE DERIVATIVES; TREATMENT OF CARDIOVASCULAR DISORDERS, KIDNEY DISORDERS SMITHKLINE BEECHAM CORPORATION (US) 1998-02-10 US disclosed
CN-1163604-A Substituted 4-diarylbutanoic or 5-diarylpentanoic acids and derivatives thereof as matrix metalloproteinase inhibitors BAYER AG (US) 1997-10-29 CN disclosed
EP-0790974-A1 SUBSTITUTED 4-BIARYLBUTYRIC OR 5-BIARYLPENTANOIC ACIDS AND DERIVATIVES AS MATRIX METALLOPROTEASE INHIBITIORS Bayer Corporation (US) 1997-08-27 EP disclosed
WO-1997017341-A1 A PROCESS OF MAKING 3-PHENYL-1-METHYLENEDIOXYPHENYL-INDANE-2-CARBOXYLIC ACID DERIVATIVES SMITHKLINE BEECHAM CORPORATION (US) 1997-05-15 WO disclosed
WO-1996015096-A1 SUBSTITUTED 4-BIARYLBUTYRIC OR 5-BIARYLPENTANOIC ACIDS AND DERIVATIVES AS MATRIX METALLOPROTEASE INHIBITIORS BAYER CORPORATION (US) 1996-05-23 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20260092031-A1 METHOD FOR PREPARING 2-HYDROXYETHYL AMINOCAPROATE COMPOUND AND USE THEREOF CBR1, ALKBH3, CYP11B1 TSHR 2152/4885IDO1 2841/4885SLC1A3 348/4885
US-20250034120-A1 PYRIDAZINONES AS PARP7 INHIBITORS PARP2, PARP1, PARP4 TSHR 3587/4885IDO1 1090/4885SLC1A3 4627/4885
US-20250064750-A1 LIPID AND COMPOSITION USED FOR DELIVERY H1-0, H1-2, H1-3 TSHR 2127/4885IDO1 3722/4885SLC1A3 1119/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.